{"title":"Hepatitis B Virus Infection: What Is Current and New.","authors":"Marion G Peters","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatitis B virus (HBV) infection is a lifelong dynamic disease that can be controlled with treatment but cannot yet be cured. Risk of end-stage liver disease and hepatocellular carcinoma (HCC) increases with ongoing inflammation and HBV viremia. Initial treatments consist of tenofovir or entecavir. Patients who require treatment include those with chronic hepatitis, cirrhosis, HCC, or HIV coinfection; patients receiving immunosuppressive treatments; and women in the third trimester of pregnancy who have elevated HBV DNA level. A number of virologic and host immune approaches are being investigated with the aim of achieving HBV eradication. This article summarizes an IAS-USA webinar given by Marion G. Peters, MD, on June 14, 2018.</p>","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":"26 4","pages":"112-116"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372357/pdf/tam-26-112.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Topics in antiviral medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Hepatitis B virus (HBV) infection is a lifelong dynamic disease that can be controlled with treatment but cannot yet be cured. Risk of end-stage liver disease and hepatocellular carcinoma (HCC) increases with ongoing inflammation and HBV viremia. Initial treatments consist of tenofovir or entecavir. Patients who require treatment include those with chronic hepatitis, cirrhosis, HCC, or HIV coinfection; patients receiving immunosuppressive treatments; and women in the third trimester of pregnancy who have elevated HBV DNA level. A number of virologic and host immune approaches are being investigated with the aim of achieving HBV eradication. This article summarizes an IAS-USA webinar given by Marion G. Peters, MD, on June 14, 2018.
乙型肝炎病毒(HBV)感染是一种终身动态疾病，可以通过治疗控制，但尚不能治愈。终末期肝病和肝细胞癌(HCC)的风险随着持续的炎症和HBV病毒血症而增加。最初的治疗包括替诺福韦或恩替卡韦。需要治疗的患者包括慢性肝炎、肝硬化、HCC或HIV合并感染患者;接受免疫抑制治疗的患者;以及在妊娠晚期HBV DNA水平升高的妇女。正在研究一些病毒学和宿主免疫方法，目的是实现HBV根除。本文总结了医学博士Marion G. Peters于2018年6月14日在IAS-USA举办的网络研讨会。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
